{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,10]],"date-time":"2026-10-10T09:06:34Z","timestamp":1791623194547,"version":"4.3.4"},"reference-count":110,"publisher":"Centers for Disease Control MMWR Office","issue":"8","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["MMWR Recomm. Rep."],"DOI":"10.15585\/mmwr.rr6908a1","type":"journal-article","created":{"date-parts":[[2020,8,20]],"date-time":"2020-08-20T13:29:40Z","timestamp":1597930180000},"page":"1-24","source":"Crossref","is-referenced-by-count":299,"title":["Prevention and Control of Seasonal Influenza with Vaccines: Recommendations of the Advisory Committee on Immunization Practices \u2014 United States, 2020\u201321 Influenza Season"],"prefix":"10.15585","volume":"69","author":[{"given":"Lisa A.","family":"Grohskopf","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Elif","family":"Alyanak","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Karen R.","family":"Broder","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lenee H.","family":"Blanton","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alicia M.","family":"Fry","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Daniel B.","family":"Jernigan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Robert L.","family":"Atmar","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"6224","published-online":{"date-parts":[[2020,8,21]]},"reference":[{"key":"key-10.15585\/mmwr.rr6908a1-202008200929-R1","doi-asserted-by":"publisher","first-page":"761","DOI":"10.2105\/AJPH.76.7.761","article-title":"Excess pneumonia and influenza associated hospitalization during influenza epidemics in the United States, 1970\u201378.","volume":"76","author":"Barker","year":"1986","journal-title":"Am J Public Health"},{"key":"key-10.15585\/mmwr.rr6908a1-202008200929-R2","doi-asserted-by":"publisher","first-page":"798","DOI":"10.1093\/oxfordjournals.aje.a113052","article-title":"Impact of epidemic type A influenza in a defined adult population.","volume":"112","author":"Barker","year":"1980","journal-title":"Am J Epidemiol"},{"key":"key-10.15585\/mmwr.rr6908a1-202008200929-R3","doi-asserted-by":"publisher","first-page":"207","DOI":"10.1542\/peds.2012-1255","article-title":"The burden of influenza in young children, 2004\u20132009.","volume":"131","author":"Poehling","year":"2013","journal-title":"Pediatrics"},{"key":"key-10.15585\/mmwr.rr6908a1-202008200929-R4","doi-asserted-by":"publisher","first-page":"31","DOI":"10.1056\/NEJMoa054869","article-title":"The underrecognized burden of influenza in young children.","volume":"355","author":"Poehling","year":"2006","journal-title":"N Engl J Med"},{"key":"key-10.15585\/mmwr.rr6908a1-202008200929-R5","doi-asserted-by":"publisher","first-page":"1517","DOI":"10.1001\/jama.2010.479","article-title":"Pandemic 2009 influenza A(H1N1) virus illness among pregnant women in the United States.","volume":"303","author":"Siston","year":"2010","journal-title":"JAMA"},{"key":"key-10.15585\/mmwr.rr6908a1-202008200929-R6","doi-asserted-by":"publisher","first-page":"846","DOI":"10.1016\/j.vaccine.2006.09.041","article-title":"Influenza- and RSV-associated hospitalizations among adults.","volume":"25","author":"Mullooly","year":"2007","journal-title":"Vaccine"},{"key":"key-10.15585\/mmwr.rr6908a1-202008200929-R7","doi-asserted-by":"publisher","first-page":"22","DOI":"10.1111\/irv.12504","article-title":"Risk factors for serious outcomes associated with influenza illness in high- versus low- and middle-income countries: systematic literature review and meta-analysis.","volume":"12","author":"Coleman","year":"2018","journal-title":"Influenza Other Respir Viruses"},{"key":"key-10.15585\/mmwr.rr6908a1-202008200929-R8","doi-asserted-by":"publisher","first-page":"1135","DOI":"10.1097\/JOM.0000000000001120","article-title":"Influenza and workplace productivity loss in working adults.","volume":"59","author":"Van Wormer","year":"2017","journal-title":"J Occup Environ Med"},{"key":"key-10.15585\/mmwr.rr6908a1-202008200929-R9","doi-asserted-by":"publisher","first-page":"18","DOI":"10.1111\/irv.12604","article-title":"The impact of influenza infection on young children, their family and the health care system.","volume":"13","author":"Willis","year":"2019","journal-title":"Influenza Other Respir Viruses"},{"key":"key-10.15585\/mmwr.rr6908a1-202008200929-R10","doi-asserted-by":"publisher","first-page":"171","DOI":"10.1111\/irv.12506","article-title":"Effects of seasonal and pandemic influenza on health-related quality of life, work and school absence in England: results from the Flu Watch cohort study.","volume":"12","author":"Fragaszy","year":"2018","journal-title":"Influenza Other Respir Viruses"},{"key":"key-10.15585\/mmwr.rr6908a1-202008200929-R11","article-title":"Prevention and control of influenza with vaccines: recommendations of the Advisory Committee on Immunization Practices (ACIP), 2010.","volume":"59","author":"Fiore","year":"2010","journal-title":"MMWR Recomm Rep"},{"key":"key-10.15585\/mmwr.rr6908a1-202008200929-R12","unstructured":"CDC. How flu vaccine effectiveness and efficacy is measured: questions and answers. Atlanta, GA: US Department of Health and Human Services, CDC. https:\/\/www.cdc.gov\/flu\/professionals\/vaccination\/effectivenessqa.htm"},{"key":"key-10.15585\/mmwr.rr6908a1-202008200929-R13","doi-asserted-by":"publisher","first-page":"132","DOI":"10.1111\/irv.12486","article-title":"Annual estimates of the burden of seasonal influenza in the United States: a tool for strengthening influenza surveillance and preparedness.","volume":"12","author":"Rolfes","year":"2018","journal-title":"Influenza Other Respir Viruses"},{"key":"key-10.15585\/mmwr.rr6908a1-202008200929-R14","doi-asserted-by":"publisher","first-page":"1845","DOI":"10.1093\/cid\/ciz075","article-title":"Effects of influenza vaccination in the United States during the 2017\u20132018 influenza season.","volume":"69","author":"Rolfes","year":"2019","journal-title":"Clin Infect Dis"},{"key":"key-10.15585\/mmwr.rr6908a1-202008200929-R15","doi-asserted-by":"publisher","first-page":"140","DOI":"10.15585\/mmwr.mm6905e1","article-title":"Initial public health response and interim clinical guidance for the 2019 novel coronavirus outbreak\u2014United States, December 31, 2019\u2013February 4, 2020.","volume":"69","author":"Patel","year":"2020","journal-title":"MMWR Morb Mortal Wkly Rep"},{"key":"key-10.15585\/mmwr.rr6908a1-202008200929-R16","unstructured":"World Health Organization. WHO Director-General\u2019s opening remarks at the media briefing on COVID-19; March 11, 2020. https:\/\/www.who.int\/dg\/speeches\/detail\/who-director-general-s-opening-remarks-at-the-media-briefing-on-covid-19---11-march-2020"},{"key":"key-10.15585\/mmwr.rr6908a1-202008200929-R17","doi-asserted-by":"publisher","first-page":"458","DOI":"10.15585\/mmwr.mm6915e3","article-title":"Hospitalization rates and characteristics of patients hospitalized with laboratory-confirmed coronavirus disease 2019\u2014COVID-NET, 14 states, March 1\u201330, 2020.","volume":"69","author":"Garg","year":"2020","journal-title":"MMWR Morb Mortal Wkly Rep"},{"key":"key-10.15585\/mmwr.rr6908a1-202008200929-R18","doi-asserted-by":"publisher","first-page":"1","DOI":"10.15585\/mmwr.rr6803a1","article-title":"Prevention and control of seasonal influenza with vaccines: recommendations of the Advisory Committee on Immunization Practices\u2014United States, 2019\u201320 influenza season.","volume":"68","author":"Grohskopf","year":"2019","journal-title":"MMWR Recomm Rep"},{"key":"key-10.15585\/mmwr.rr6908a1-202008200929-R19","unstructured":"Ahmed F. ACIP handbook for developing evidence-based recommendations, Version 1.2. Atlanta, GA: US Department of Health and Human Services, CDC; 2013."},{"key":"key-10.15585\/mmwr.rr6908a1-202008200929-R20","unstructured":"CDC. The flu season. Atlanta, GA: US Department of Health and Human Services, CDC; 2015. https:\/\/www.cdc.gov\/flu\/about\/season\/flu-season.htm"},{"key":"key-10.15585\/mmwr.rr6908a1-202008200929-R21","doi-asserted-by":"publisher","first-page":"18","DOI":"10.2807\/ese.18.05.20388-en","article-title":"Decline in influenza vaccine effectiveness with time after vaccination, Navarre, Spain, season 2011\/12.","volume":"18","author":"Castilla","year":"2013","journal-title":"Euro Surveill"},{"key":"key-10.15585\/mmwr.rr6908a1-202008200929-R22","doi-asserted-by":"publisher","first-page":"18","DOI":"10.2807\/ese.18.05.20390-en","article-title":"Low and decreasing vaccine effectiveness against influenza A(H3) in 2011\/12 among vaccination target groups in Europe: results from the I-MOVE multicentre case-control study.","volume":"18","author":"Kissling","year":"2013","journal-title":"Euro Surveill"},{"key":"key-10.15585\/mmwr.rr6908a1-202008200929-R23","doi-asserted-by":"publisher","first-page":"246","DOI":"10.1016\/j.vaccine.2014.06.052","article-title":"Waning vaccine protection against influenza A (H3N2) illness in children and older adults during a single season.","volume":"33","author":"Belongia","year":"2015","journal-title":"Vaccine"},{"key":"key-10.15585\/mmwr.rr6908a1-202008200929-R24","doi-asserted-by":"publisher","first-page":"3907","DOI":"10.1016\/j.vaccine.2016.05.034","article-title":"Influenza vaccine effectiveness: maintained protection throughout the duration of influenza seasons 2010\u20132011 through 2013\u20132014.","volume":"34","author":"Radin","year":"2016","journal-title":"Vaccine"},{"key":"key-10.15585\/mmwr.rr6908a1-202008200929-R25","first-page":"544","article-title":"Intraseason waning of influenza vaccine protection: evidence from the U.S. Influenza Vaccine Effectiveness Network, 2011\u201312 through 2014\u201315.","volume":"64","author":"Ferdinands","year":"2017","journal-title":"Clin Infect Dis"},{"key":"key-10.15585\/mmwr.rr6908a1-202008200929-R26","doi-asserted-by":"publisher","first-page":"5799","DOI":"10.1016\/j.vaccine.2017.09.035","article-title":"Waning protection of influenza vaccination during four influenza seasons, 2011\/2012 to 2014\/2015.","volume":"35","author":"Puig-Barber\u00e0","year":"2017","journal-title":"Vaccine"},{"key":"key-10.15585\/mmwr.rr6908a1-202008200929-R27","doi-asserted-by":"publisher","first-page":"1623","DOI":"10.1093\/cid\/ciy770","article-title":"Intraseason waning of influenza vaccine effectiveness.","volume":"68","author":"Ray","year":"2019","journal-title":"Clin Infect Dis"},{"key":"key-10.15585\/mmwr.rr6908a1-202008200929-R28","doi-asserted-by":"publisher","first-page":"21","DOI":"10.2807\/1560-7917.ES.2016.21.16.30201","article-title":"I-MOVE multicentre case-control study 2010\/11 to 2014\/15: is there within-season waning of influenza type\/subtype vaccine effectiveness with increasing time since vaccination?","volume":"21","author":"Kissling","year":"2016","journal-title":"Euro Surveill"},{"key":"key-10.15585\/mmwr.rr6908a1-202008200929-R29","doi-asserted-by":"publisher","first-page":"18","DOI":"10.2807\/ese.18.05.20389-en","article-title":"Vaccine effectiveness of 2011\/12 trivalent seasonal influenza vaccine in preventing laboratory-confirmed influenza in primary care in the United Kingdom: evidence of waning intra-seasonal protection.","volume":"18","author":"Pebody","year":"2013","journal-title":"Euro Surveill"},{"key":"key-10.15585\/mmwr.rr6908a1-202008200929-R30","doi-asserted-by":"publisher","first-page":"1142","DOI":"10.1093\/infdis\/jiw105","article-title":"Modest waning of influenza vaccine efficacy and antibody titers during the 2007\u20132008 influenza season.","volume":"214","author":"Petrie","year":"2016","journal-title":"J Infect Dis"},{"key":"key-10.15585\/mmwr.rr6908a1-202008200929-R31","doi-asserted-by":"crossref","unstructured":"Ferdinands JM, Alyanak E, Reed C, Fry AM. Waning of influenza vaccine protection: exploring the trade-offs of changes in vaccination timing among older adults. Clin Infect Dis 2020;70:1550-59.","DOI":"10.1093\/cid\/ciz452"},{"key":"key-10.15585\/mmwr.rr6908a1-202008200929-R32","article-title":"Immunization of health-care personnel: recommendations of the Advisory Committee on Immunization Practices (ACIP).","volume":"60","author":"CDC","year":"2011","journal-title":"MMWR Recomm Rep"},{"key":"key-10.15585\/mmwr.rr6908a1-202008200929-R33","article-title":"Influenza vaccination of health-care personnel: recommendations of the Healthcare Infection Control Practices Advisory Committee (HICPAC) and the Advisory Committee on Immunization Practices (ACIP).","volume":"55","author":"Pearson","year":"2006","journal-title":"MMWR Recomm Rep"},{"key":"key-10.15585\/mmwr.rr6908a1-202008200929-R34","doi-asserted-by":"publisher","first-page":"1032","DOI":"10.1086\/507309","article-title":"Immunogenicity and reactogenicity of 1 versus 2 doses of trivalent inactivated influenza vaccine in vaccine-naive 5\u20138-year-old children.","volume":"194","author":"Neuzil","year":"2006","journal-title":"J Infect Dis"},{"key":"key-10.15585\/mmwr.rr6908a1-202008200929-R35","doi-asserted-by":"publisher","first-page":"755","DOI":"10.1016\/j.jpeds.2006.06.036","article-title":"Influenza vaccine effectiveness in healthy 6- to 21-month-old children during the 2003\u20132004 season.","volume":"149","author":"Allison","year":"2006","journal-title":"J Pediatr"},{"key":"key-10.15585\/mmwr.rr6908a1-202008200929-R36","doi-asserted-by":"publisher","first-page":"153","DOI":"10.1542\/peds.2005-0049","article-title":"Effectiveness of the 2003\u20132004 influenza vaccine among children 6 months to 8 years of age, with 1 vs 2 doses.","volume":"116","author":"Ritzwoller","year":"2005","journal-title":"Pediatrics"},{"key":"key-10.15585\/mmwr.rr6908a1-202008200929-R37","doi-asserted-by":"publisher","first-page":"911","DOI":"10.1542\/peds.2007-3304","article-title":"Vaccine effectiveness against laboratory-confirmed influenza in children 6 to 59 months of age during the 2003\u20132004 and 2004\u20132005 influenza seasons.","volume":"122","author":"Eisenberg","year":"2008","journal-title":"Pediatrics"},{"key":"key-10.15585\/mmwr.rr6908a1-202008200929-R38","doi-asserted-by":"publisher","first-page":"e109","DOI":"10.1097\/AOG.0000000000002588","article-title":"ACOG Committee opinion no. 732: influenza vaccination during pregnancy.","volume":"131","author":"ACOG Committee on Obstetric Practice","year":"2018","journal-title":"Obstet Gynecol"},{"key":"key-10.15585\/mmwr.rr6908a1-202008200929-R39","doi-asserted-by":"publisher","first-page":"e214","DOI":"10.1097\/AOG.0000000000002662","article-title":"ACOG Committee opinion no. 741: maternal immunization.","volume":"131","author":"ACOG Infectious Disease and Public Health Preparedness Expert Work Group","year":"2018","journal-title":"Obstet Gynecol"},{"key":"key-10.15585\/mmwr.rr6908a1-202008200929-R40","doi-asserted-by":"publisher","first-page":"177.e1","DOI":"10.1016\/j.ajog.2012.07.007","article-title":"Safety of MF59-adjuvanted A\/H1N1 influenza vaccine in pregnancy: a comparative cohort study.","volume":"207","author":"Heikkinen","year":"2012","journal-title":"Am J Obstet Gynecol"},{"key":"key-10.15585\/mmwr.rr6908a1-202008200929-R41","doi-asserted-by":"publisher","first-page":"4445","DOI":"10.1016\/j.vaccine.2012.04.081","article-title":"A(H1N1)v2009: a controlled observational prospective cohort study on vaccine safety in pregnancy.","volume":"30","author":"Oppermann","year":"2012","journal-title":"Vaccine"},{"key":"key-10.15585\/mmwr.rr6908a1-202008200929-R42","doi-asserted-by":"publisher","first-page":"e2794","DOI":"10.1136\/bmj.e2794","article-title":"Vaccination against pandemic A\/H1N1 2009 influenza in pregnancy and risk of fetal death: cohort study in Denmark.","volume":"344","author":"Pasternak","year":"2012","journal-title":"BMJ"},{"key":"key-10.15585\/mmwr.rr6908a1-202008200929-R43","doi-asserted-by":"publisher","first-page":"e51734","DOI":"10.1371\/journal.pone.0051734","article-title":"Evaluating the hazard of foetal death following H1N1 influenza vaccination; a population based cohort study in the UK GPRD.","volume":"7","author":"Sammon","year":"2012","journal-title":"PLoS One"},{"key":"key-10.15585\/mmwr.rr6908a1-202008200929-R44","doi-asserted-by":"publisher","first-page":"5026","DOI":"10.1016\/j.vaccine.2013.08.097","article-title":"Risks and safety of pandemic H1N1 influenza vaccine in pregnancy: birth defects, spontaneous abortion, preterm delivery, and small for gestational age infants.","volume":"31","author":"Chambers","year":"2013","journal-title":"Vaccine"},{"key":"key-10.15585\/mmwr.rr6908a1-202008200929-R45","doi-asserted-by":"publisher","first-page":"159","DOI":"10.1097\/AOG.0b013e318279f56f","article-title":"Trivalent inactivated influenza vaccine and spontaneous abortion.","volume":"121","author":"Irving","year":"2013","journal-title":"Obstet Gynecol"},{"key":"key-10.15585\/mmwr.rr6908a1-202008200929-R46","doi-asserted-by":"publisher","first-page":"6463","DOI":"10.1016\/j.vaccine.2014.09.054","article-title":"Safety of inactivated monovalent pandemic (H1N1) 2009 vaccination during pregnancy: a population-based study in Taiwan.","volume":"32","author":"Huang","year":"2014","journal-title":"Vaccine"},{"key":"key-10.15585\/mmwr.rr6908a1-202008200929-R47","doi-asserted-by":"publisher","first-page":"1282","DOI":"10.1128\/CVI.00375-14","article-title":"Prospective cohort study of the safety of an influenza A(H1N1) vaccine in pregnant Chinese women.","volume":"21","author":"Ma","year":"2014","journal-title":"Clin Vaccine Immunol"},{"key":"key-10.15585\/mmwr.rr6908a1-202008200929-R48","doi-asserted-by":"publisher","first-page":"4443","DOI":"10.1016\/j.vaccine.2016.06.054","article-title":"Safety of the 2010\u201311, 2011\u201312, 2012\u201313, and 2013\u201314 seasonal influenza vaccines in pregnancy: Birth defects, spontaneous abortion, preterm delivery, and small for gestational age infants, a study from the cohort arm of VAMPSS.","volume":"34","author":"Chambers","year":"2016","journal-title":"Vaccine"},{"key":"key-10.15585\/mmwr.rr6908a1-202008200929-R49","doi-asserted-by":"publisher","first-page":"2108","DOI":"10.1016\/j.vaccine.2015.02.068","article-title":"Influenza vaccination during pregnancy: a systematic review of fetal death, spontaneous abortion, and congenital malformation safety outcomes.","volume":"33","author":"McMillan","year":"2015","journal-title":"Vaccine"},{"key":"key-10.15585\/mmwr.rr6908a1-202008200929-R50","doi-asserted-by":"publisher","first-page":"e11","DOI":"10.1093\/cid\/ciu915","article-title":"Maternal influenza immunization and birth outcomes of stillbirth and spontaneous abortion: a systematic review and meta-analysis.","volume":"60","author":"Bratton","year":"2015","journal-title":"Clin Infect Dis"},{"key":"key-10.15585\/mmwr.rr6908a1-202008200929-R51","doi-asserted-by":"publisher","first-page":"5314","DOI":"10.1016\/j.vaccine.2017.06.069","article-title":"Association of spontaneous abortion with receipt of inactivated influenza vaccine containing H1N1pdm09 in 2010\u201311 and 2011\u201312.","volume":"35","author":"Donahue","year":"2017","journal-title":"Vaccine"},{"key":"key-10.15585\/mmwr.rr6908a1-202008200929-R52","doi-asserted-by":"publisher","first-page":"6673","DOI":"10.1016\/j.vaccine.2019.09.035","article-title":"Inactivated influenza vaccine and spontaneous abortion in the Vaccine Safety Datalink in 2012\u201313, 2013\u201314, and 2014\u201315.","volume":"37","author":"Donahue","year":"2019","journal-title":"Vaccine"},{"key":"key-10.15585\/mmwr.rr6908a1-202008200929-R53","doi-asserted-by":"publisher","first-page":"635","DOI":"10.1056\/NEJMoa1315727","article-title":"Efficacy of high-dose versus standard-dose influenza vaccine in older adults.","volume":"371","author":"DiazGranados","year":"2014","journal-title":"N Engl J Med"},{"key":"key-10.15585\/mmwr.rr6908a1-202008200929-R54","doi-asserted-by":"publisher","first-page":"4988","DOI":"10.1016\/j.vaccine.2015.07.006","article-title":"Prevention of serious events in adults 65 years of age or older: a comparison between high-dose and standard-dose inactivated influenza vaccines.","volume":"33","author":"DiazGranados","year":"2015","journal-title":"Vaccine"},{"key":"key-10.15585\/mmwr.rr6908a1-202008200929-R55","doi-asserted-by":"publisher","first-page":"4565","DOI":"10.1016\/j.vaccine.2015.07.003","article-title":"Efficacy and immunogenicity of high-dose influenza vaccine in older adults by age, comorbidities, and frailty.","volume":"33","author":"DiazGranados","year":"2015","journal-title":"Vaccine"},{"key":"key-10.15585\/mmwr.rr6908a1-202008200929-R56","doi-asserted-by":"publisher","first-page":"2427","DOI":"10.1056\/NEJMoa1608862","article-title":"Efficacy of recombinant influenza vaccine in adults 50 years of age or older.","volume":"376","author":"Dunkle","year":"2017","journal-title":"N Engl J Med"},{"key":"key-10.15585\/mmwr.rr6908a1-202008200929-R57","doi-asserted-by":"publisher","first-page":"6122","DOI":"10.1016\/j.vaccine.2013.07.059","article-title":"The comparative effectiveness of adjuvanted and unadjuvanted trivalent inactivated influenza vaccine (TIV) in the elderly.","volume":"31","author":"Van Buynder","year":"2013","journal-title":"Vaccine"},{"key":"key-10.15585\/mmwr.rr6908a1-202008200929-R58","doi-asserted-by":"publisher","first-page":"172","DOI":"10.1086\/599790","article-title":"Randomized, double-blind controlled phase 3 trial comparing the immunogenicity of high-dose and standard-dose influenza vaccine in adults 65 years of age and older.","volume":"200","author":"Falsey","year":"2009","journal-title":"J Infect Dis"},{"key":"key-10.15585\/mmwr.rr6908a1-202008200929-R59","unstructured":"Food and Drug Administration. Clinical review: Fluad. Silver Spring, MD: US Department of Health and Human Services, Food and Drug Administration; 2015."},{"key":"key-10.15585\/mmwr.rr6908a1-202008200929-R60","unstructured":"Food and Drug Administration. Clinical review: Fluzone high-dose. Silver Spring, MD: US Department of Health and Human Services, Food and Drug Administration; 2014."},{"key":"key-10.15585\/mmwr.rr6908a1-202008200929-R61","unstructured":"Fluzone High-Dose [Package Insert]. Swiftwater, PA: Sanofi Pasteur; 2020."},{"key":"key-10.15585\/mmwr.rr6908a1-202008200929-R62","doi-asserted-by":"publisher","first-page":"1718","DOI":"10.1093\/infdis\/jiy088","article-title":"Relative vaccine effectiveness of high-dose versus standard-dose influenza vaccines among Veterans Health Administration patients.","volume":"217","author":"Young-Xu","year":"2018","journal-title":"J Infect Dis"},{"key":"key-10.15585\/mmwr.rr6908a1-202008200929-R63","doi-asserted-by":"publisher","first-page":"510","DOI":"10.1093\/infdis\/jiw641","article-title":"Comparative effectiveness of high-dose versus standard-dose influenza vaccines among U.S. Medicare beneficiaries in preventing postinfluenza deaths during 2012\u20132013 and 2013\u20132014.","volume":"215","author":"Shay","year":"2017","journal-title":"J Infect Dis"},{"key":"key-10.15585\/mmwr.rr6908a1-202008200929-R64","doi-asserted-by":"publisher","first-page":"293","DOI":"10.1016\/S1473-3099(14)71087-4","article-title":"Comparative effectiveness of high-dose versus standard-dose influenza vaccines in U.S. residents aged 65 years and older from 2012 to 2013 using Medicare data: a retrospective cohort analysis.","volume":"15","author":"Izurieta","year":"2015","journal-title":"Lancet Infect Dis"},{"key":"key-10.15585\/mmwr.rr6908a1-202008200929-R65","doi-asserted-by":"publisher","first-page":"171","DOI":"10.1093\/cid\/civ261","article-title":"Comparative effectiveness of high-dose versus standard-dose influenza vaccination in community-dwelling veterans.","volume":"61","author":"Richardson","year":"2015","journal-title":"Clin Infect Dis"},{"key":"key-10.15585\/mmwr.rr6908a1-202008200929-R66","doi-asserted-by":"publisher","first-page":"738","DOI":"10.1016\/S2213-2600(17)30235-7","article-title":"Comparative effectiveness of high-dose versus standard-dose influenza vaccination on numbers of U.S. nursing home residents admitted to hospital: a cluster-randomised trial.","volume":"5","author":"Gravenstein","year":"2017","journal-title":"Lancet Respir Med"},{"key":"key-10.15585\/mmwr.rr6908a1-202008200929-R67","doi-asserted-by":"publisher","first-page":"435","DOI":"10.1080\/14760584.2018.1471989","article-title":"Efficacy and effectiveness of high-dose versus standard-dose influenza vaccination for older adults: a systematic review and meta-analysis.","volume":"17","author":"Lee","year":"2018","journal-title":"Expert Rev Vaccines"},{"key":"key-10.15585\/mmwr.rr6908a1-202008200929-R68","unstructured":"Fluzone High-Dose Quadrivalent [Package Insert]. Swiftwater, PA: Sanofi Pasteur; 2020."},{"key":"key-10.15585\/mmwr.rr6908a1-202008200929-R69","unstructured":"Flublok Quadrivalent [Package Insert]. Meriden, CT: Protein Sciences; 2020."},{"key":"key-10.15585\/mmwr.rr6908a1-202008200929-R70","doi-asserted-by":"publisher","first-page":"527","DOI":"10.1093\/aje\/kws313","article-title":"Effectiveness of adjuvanted influenza vaccination in elderly subjects in northern Italy.","volume":"176","author":"Mannino","year":"2012","journal-title":"Am J Epidemiol"},{"key":"key-10.15585\/mmwr.rr6908a1-202008200929-R71","doi-asserted-by":"publisher","first-page":"663","DOI":"10.1080\/14760584.2019.1622418","article-title":"Adjuvanted versus nonadjuvanted influenza vaccines and risk of hospitalizations for pneumonia and cerebro\/cardiovascular events in the elderly.","volume":"18","author":"Lapi","year":"2019","journal-title":"Expert Rev Vaccines"},{"key":"key-10.15585\/mmwr.rr6908a1-202008200929-R72","unstructured":"Fluad Quadrivalent [Package Insert]. Holly Springs, NC: Seqirus; 2020."},{"key":"key-10.15585\/mmwr.rr6908a1-202008200929-R73","unstructured":"CDC. Influenza antiviral medications: summary for clinicians. Atlanta, GA: US Department of Health and Human Services, CDC. https:\/\/www.cdc.gov\/flu\/professionals\/antivirals\/summary-clinicians.htm"},{"key":"key-10.15585\/mmwr.rr6908a1-202008200929-R74","unstructured":"Ezeanolue E, Harriman K, Hunter P, Kroger A, Pellegrini C. General best practice guidelines for immunization: best practices guidance of the Advisory Committee on Immunization Practices (ACIP). https:\/\/www.cdc.gov\/vaccines\/hcp\/acip-recs\/general-recs\/downloads\/general-recs.pdf"},{"key":"key-10.15585\/mmwr.rr6908a1-202008200929-R75","doi-asserted-by":"publisher","first-page":"1095","DOI":"10.1086\/374053","article-title":"Large summertime influenza A outbreak among tourists in Alaska and the Yukon Territory.","volume":"36","author":"Uyeki","year":"2003","journal-title":"Clin Infect Dis"},{"key":"key-10.15585\/mmwr.rr6908a1-202008200929-R76","doi-asserted-by":"publisher","first-page":"1282","DOI":"10.1086\/429243","article-title":"Influenza virus infection in travelers to tropical and subtropical countries.","volume":"40","author":"Mutsch","year":"2005","journal-title":"Clin Infect Dis"},{"key":"key-10.15585\/mmwr.rr6908a1-202008200929-R77","doi-asserted-by":"publisher","first-page":"54","DOI":"10.1016\/j.jcv.2013.01.008","article-title":"Incidence and risk factors for acute respiratory illnesses and influenza virus infections in Australian travellers to Asia.","volume":"57","author":"Ratnam","year":"2013","journal-title":"J Clin Virol"},{"key":"key-10.15585\/mmwr.rr6908a1-202008200929-R78","doi-asserted-by":"publisher","first-page":"306","DOI":"10.1111\/jtm.12215","article-title":"Influenza outbreaks among passengers and crew on two cruise ships: a recent account of preparedness and response to an ever-present challenge.","volume":"22","author":"Millman","year":"2015","journal-title":"J Travel Med"},{"key":"key-10.15585\/mmwr.rr6908a1-202008200929-R79","unstructured":"Flumist Quadrivalent [Package Insert]. Gaithersburg, MD: MedImmune; 2020."},{"key":"key-10.15585\/mmwr.rr6908a1-202008200929-R80","unstructured":"Rapivab (peramivir for injection) [Package Insert]. Durham, NC: BioCryst; 2017."},{"key":"key-10.15585\/mmwr.rr6908a1-202008200929-R81","unstructured":"Xofluza (baloxavir marboxil) [Package Insert]. San Francisco, CA: Genentech; 2018. https:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/label\/2018\/210854s000lbl.pdf"},{"key":"key-10.15585\/mmwr.rr6908a1-202008200929-R82","unstructured":"Food and Drug Administration. Guidance for industry: bioavailability and bioequivalence studies for orally administered drug products: general considerations. Silver Spring, MD: US Department of Health and Human Services, Food and Drug Administration; 2003."},{"key":"key-10.15585\/mmwr.rr6908a1-202008200929-R83","doi-asserted-by":"publisher","first-page":"1499","DOI":"10.1111\/j.1532-5415.2007.01397.x","article-title":"Safety and immunogenicity profile of the concomitant administration of ZOSTAVAX and inactivated influenza vaccine in adults aged 50 and older.","volume":"55","author":"Kerzner","year":"2007","journal-title":"J Am Geriatr Soc"},{"key":"key-10.15585\/mmwr.rr6908a1-202008200929-R84","doi-asserted-by":"publisher","first-page":"179","DOI":"10.1016\/j.vaccine.2017.08.029","article-title":"Immunogenicity and safety of zoster vaccine live administered with quadrivalent influenza virus vaccine.","volume":"36","author":"Levin","year":"2018","journal-title":"Vaccine"},{"key":"key-10.15585\/mmwr.rr6908a1-202008200929-R85","doi-asserted-by":"publisher","first-page":"1296","DOI":"10.1128\/CVI.00176-12","article-title":"Randomized, controlled trial of a 13-valent pneumococcal conjugate vaccine administered concomitantly with an influenza vaccine in healthy adults.","volume":"19","author":"Frenck","year":"2012","journal-title":"Clin Vaccine Immunol"},{"key":"key-10.15585\/mmwr.rr6908a1-202008200929-R86","doi-asserted-by":"publisher","first-page":"5195","DOI":"10.1016\/j.vaccine.2011.05.031","article-title":"A randomized, double-blind trial to evaluate immunogenicity and safety of 13-valent pneumococcal conjugate vaccine given concomitantly with trivalent influenza vaccine in adults aged \u226565 years.","volume":"29","author":"Schwarz","year":"2011","journal-title":"Vaccine"},{"key":"key-10.15585\/mmwr.rr6908a1-202008200929-R87","doi-asserted-by":"publisher","first-page":"3464","DOI":"10.1016\/j.vaccine.2006.12.047","article-title":"Comparison of the safety and immunogenicity of concomitant and sequential administration of an adult formulation tetanus and diphtheria toxoids adsorbed combined with acellular pertussis (Tdap) vaccine and trivalent inactivated influenza vaccine in adults.","volume":"25","author":"McNeil","year":"2007","journal-title":"Vaccine"},{"key":"key-10.15585\/mmwr.rr6908a1-202008200929-R88","doi-asserted-by":"publisher","first-page":"1923","DOI":"10.1080\/21645515.2018.1455476","article-title":"Immunogenicity of simultaneous versus sequential administration of a 23-valent pneumococcal polysaccharide vaccine and a quadrivalent influenza vaccine in older individuals: a randomized, open-label, non-inferiority trial.","volume":"14","author":"Nakashima","year":"2018","journal-title":"Hum Vaccin Immunother"},{"key":"key-10.15585\/mmwr.rr6908a1-202008200929-R89","doi-asserted-by":"publisher","first-page":"4647","DOI":"10.1016\/j.vaccine.2015.05.003","article-title":"Immunogenicity and safety of concomitant MF59-adjuvanted influenza vaccine and 23-valent pneumococcal polysaccharide vaccine administration in older adults.","volume":"33","author":"Song","year":"2015","journal-title":"Vaccine"},{"key":"key-10.15585\/mmwr.rr6908a1-202008200929-R90","doi-asserted-by":"publisher","first-page":"1069","DOI":"10.1097\/AOG.0000000000001066","article-title":"Safety of tetanus toxoid, reduced diphtheria toxoid, and acellular pertussis and influenza vaccinations in pregnancy.","volume":"126","author":"Sukumaran","year":"2015","journal-title":"Obstet Gynecol"},{"key":"key-10.15585\/mmwr.rr6908a1-202008200929-R91","doi-asserted-by":"publisher","first-page":"211","DOI":"10.1001\/jamapediatrics.2013.4469","article-title":"Risk of fever after pediatric trivalent inactivated influenza vaccine and 13-valent pneumococcal conjugate vaccine.","volume":"168","author":"Stockwell","year":"2014","journal-title":"JAMA Pediatr"},{"key":"key-10.15585\/mmwr.rr6908a1-202008200929-R92","doi-asserted-by":"publisher","first-page":"e20191909","DOI":"10.1542\/peds.2019-1909","article-title":"Fever after influenza, diphtheria-tetanus-acellular pertussis, and pneumococcal vaccinations.","volume":"145","author":"Walter","year":"2020","journal-title":"Pediatrics"},{"key":"key-10.15585\/mmwr.rr6908a1-202008200929-R93","doi-asserted-by":"publisher","first-page":"e20160320","DOI":"10.1542\/peds.2016-0320","article-title":"Febrile seizure risk after vaccination in children 6 to 23 months.","volume":"138","author":"Duffy","year":"2016","journal-title":"Pediatrics"},{"key":"key-10.15585\/mmwr.rr6908a1-202008200929-R94","doi-asserted-by":"publisher","first-page":"928","DOI":"10.1002\/pds.3996","article-title":"Post licensure surveillance of influenza vaccines in the Vaccine Safety Datalink in the 2013-2014 and 2014-2015 seasons.","volume":"25","author":"Li","year":"2016","journal-title":"Pharmacoepidemiol Drug Saf"},{"key":"key-10.15585\/mmwr.rr6908a1-202008200929-R95","doi-asserted-by":"publisher","first-page":"249","DOI":"10.3928\/00904481-20131122-09","article-title":"Febrile seizures.","volume":"42","author":"Patterson","year":"2013","journal-title":"Pediatr Ann"},{"key":"key-10.15585\/mmwr.rr6908a1-202008200929-R96","doi-asserted-by":"publisher","first-page":"6383","DOI":"10.1016\/j.vaccine.2008.08.046","article-title":"Safety and immunogenicity of a prototype adjuvanted inactivated split-virus influenza A (H5N1) vaccine in infants and children.","volume":"26","author":"Nolan","year":"2008","journal-title":"Vaccine"},{"key":"key-10.15585\/mmwr.rr6908a1-202008200929-R97","doi-asserted-by":"publisher","first-page":"1566","DOI":"10.1016\/j.vaccine.2009.11.054","article-title":"Influenza vaccine concurrently administered with a combination measles, mumps, and rubella vaccine to young children.","volume":"28","author":"Lum","year":"2010","journal-title":"Vaccine"},{"key":"key-10.15585\/mmwr.rr6908a1-202008200929-R98","unstructured":"Shingrix [Package Insert]. Research Triangle Park, NC: GlaxoSmithKline; 2017."},{"key":"key-10.15585\/mmwr.rr6908a1-202008200929-R99","unstructured":"Fluad [Package Insert]. Holly Springs, NC: Seqirus; 2020."},{"key":"key-10.15585\/mmwr.rr6908a1-202008200929-R100","unstructured":"Heplisav-B [Package Insert]. Emeryville, CA: Dynavax; 2017."},{"key":"key-10.15585\/mmwr.rr6908a1-202008200929-R101","doi-asserted-by":"publisher","first-page":"1352","DOI":"10.1093\/infdis\/jix481","article-title":"Immunogenicity and safety of an adjuvanted herpes zoster subunit vaccine coadministered with seasonal influenza vaccine in adults aged 50 years or older.","volume":"216","author":"Schwarz","year":"2017","journal-title":"J Infect Dis"},{"key":"key-10.15585\/mmwr.rr6908a1-202008200929-R102","unstructured":"Afluria Quadrivalent [Package Insert]. Parkville, Victoria, Australia: Seqirus; 2020."},{"key":"key-10.15585\/mmwr.rr6908a1-202008200929-R103","unstructured":"Fluarix Quadrivalent [Package Insert]. Dresden, Germany: GlaxoSmithKline; 2020."},{"key":"key-10.15585\/mmwr.rr6908a1-202008200929-R104","unstructured":"FluLaval Quadrivalent [Package Insert]. Quebec City, QC, Canada: ID Biomedical Corporation of Quebec; 2020."},{"key":"key-10.15585\/mmwr.rr6908a1-202008200929-R105","unstructured":"Fluzone Quadrivalent [Package Insert]. Swiftwater, PA: Sanofi Pasteur; 2020."},{"key":"key-10.15585\/mmwr.rr6908a1-202008200929-R106","unstructured":"Flucelvax Quadrivalent [Package Insert]. Holly Springs, NC: Seqirus; 2020."},{"key":"key-10.15585\/mmwr.rr6908a1-202008200929-R107","doi-asserted-by":"publisher","first-page":"5825","DOI":"10.1016\/j.vaccine.2019.08.016","article-title":"Safety and immunogenicity of high-dose quadrivalent influenza vaccine in adults \u226565\u202fyears of age: a phase 3 randomized clinical trial.","volume":"37","author":"Chang","year":"2019","journal-title":"Vaccine"},{"key":"key-10.15585\/mmwr.rr6908a1-202008200929-R108","unstructured":"Food and Drug Administration. Clinical review: Fluad Quadrivalent. Silver Spring, MD: US Department of Health and Human Services, Food and Drug Administration; 2020."},{"key":"key-10.15585\/mmwr.rr6908a1-202008200929-R109","doi-asserted-by":"publisher","first-page":"242","DOI":"10.1016\/j.vaccine.2019.10.021","article-title":"Immunogenicity and safety of MF59-adjuvanted quadrivalent influenza vaccine versus standard and alternate B strain MF59-adjuvanted trivalent influenza vaccines in older adults.","volume":"38","author":"Essink","year":"2020","journal-title":"Vaccine"},{"key":"key-10.15585\/mmwr.rr6908a1-202008200929-R110","unstructured":"Health Resources and Services Administration. What you need to know about the National Vaccine Injury Compensation Program (VICP). Washington, DC: US Department of Health and Human Services, Health Resources and Services Administration; 2019. https:\/\/www.hrsa.gov\/sites\/default\/files\/hrsa\/vaccine-compensation\/resources\/about-vaccine-injury-compensation-program-booklet.pdf"}],"container-title":["MMWR. Recommendations and Reports"],"original-title":[],"deposited":{"date-parts":[[2020,8,20]],"date-time":"2020-08-20T13:29:54Z","timestamp":1597930194000},"score":1,"resource":{"primary":{"URL":"http:\/\/www.cdc.gov\/mmwr\/volumes\/69\/rr\/rr6908a1.htm?s_cid=rr6908a1_w"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,8,21]]},"references-count":110,"journal-issue":{"issue":"8","published-online":{"date-parts":[[2020,8,21]]}},"URL":"https:\/\/doi.org\/10.15585\/mmwr.rr6908a1","relation":{},"ISSN":["1057-5987","1545-8601"],"issn-type":[{"value":"1057-5987","type":"print"},{"value":"1545-8601","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2020,8,21]]},"published":{"date-parts":[[2020,8,21]]}}}